| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11014692 | Annals of Allergy, Asthma & Immunology | 2018 | 23 Pages |
Abstract
Monitoring baseline characteristics of patients before introduction of omalizumab therapy may help to predict treatment outcome in CSU patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Eustachio MD, Luca MD, PhD, MSc, Elisabetta MD, PhD, Fabio MD, PhD, Aikaterini MD, PhD, Giorgio Walter MD, Italian OCUReL study group Italian OCUReL study group,